30.21
0.51 (1.72%)
| Penutupan Terdahulu | 29.70 |
| Buka | 29.56 |
| Jumlah Dagangan | 597,589 |
| Purata Dagangan (3B) | 349,431 |
| Modal Pasaran | 751,356,736 |
| Harga / Jualan (P/S) | 411.22 |
| Harga / Buku (P/B) | 5.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Nov 2025 |
| EPS Cair (TTM) | -19.84 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.16% |
| Nisbah Semasa (MRQ) | 21.11 |
| Aliran Tunai Operasi (OCF TTM) | -108.63 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -65.95 M |
| Pulangan Atas Aset (ROA TTM) | -44.72% |
| Pulangan Atas Ekuiti (ROE TTM) | -75.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | RAPT Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 5.0 |
| Osilator Teknikal | 4.0 |
| Purata | 2.13 |
|
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.42% |
| % Dimiliki oleh Institusi | 99.41% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 72.00 (HC Wainwright & Co., 138.33%) | Beli |
| 72.00 (Wells Fargo, 138.33%) | Beli | |
| Median | 60.00 (98.61%) | |
| Rendah | 37.00 (Leerink Partners, 22.48%) | Beli |
| Purata | 60.57 (100.50%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 29.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JP Morgan | 12 Nov 2025 | 57.00 (88.68%) | Beli | 29.40 |
| 20 Oct 2025 | 55.00 (82.06%) | Beli | 33.67 | |
| Barclays | 07 Nov 2025 | 56.00 (85.37%) | Beli | 28.86 |
| 21 Oct 2025 | 58.00 (91.99%) | Beli | 33.53 | |
| Wells Fargo | 03 Nov 2025 | 72.00 (138.33%) | Beli | 29.35 |
| 21 Oct 2025 | 48.00 (58.89%) | Beli | 33.53 | |
| Guggenheim | 27 Oct 2025 | 70.00 (131.71%) | Beli | 30.10 |
| HC Wainwright & Co. | 27 Oct 2025 | 72.00 (138.33%) | Beli | 30.10 |
| Clear Street | 21 Oct 2025 | 60.00 (98.61%) | Beli | 33.53 |
| 30 Sep 2025 | 41.00 (35.72%) | Beli | 25.79 | |
| Leerink Partners | 26 Sep 2025 | 37.00 (22.48%) | Beli | 26.38 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |